Sclerosing cholangitis epidemiology and etiology

Journal of Gastrointestinal Surgery

Volumn 12, Issue 3, 2008, Pages 417-419

  Lazaridis, Konstantinos N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholestasis; Epidemiology; Pathogenesis

Indexed keywords

ARTICLE; GENETICS; HEPATIC DUCT; HUMAN; INTRAHEPATIC BILE DUCT; PATHOLOGY; PROGNOSIS; SCLEROSING CHOLANGITIS;

BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CHOLANGITIS, SCLEROSING; HUMANS; PROGNOSIS;

EID: 38949208761     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0344-3     Document Type: Article

References (21)

1. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-1369.
2. Gossard AA, Angulo P, Lindor KD. Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005;100:1330-1333.
3. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577.
4. Quigley EM, LaRusso NF, Ludwig J, et al. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983;85:1160-1165.
5. Bergquist A, Lindberg G, Saarinen S, Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005;42:252-256.
6. Chapman RW, Varghese Z, Gaul R, et al. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24:38-41.
7. Donaldson PT, Farrant JM, Wilkinson ML, et al. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991;13:129-133.
8. Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999;53:459-469.
9. Mitchell SA, Grove J, Spurkland A, et al. Association of the tumour necrosis factor alpha-308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001;49:288-294.
10. Satsangi J, Chapman RW, Haldar N, et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001;121:124-130.
11. Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001;120:1475-1482.
12. Eri R, Jonsson JR, Pandeya N, et al. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 2004;5:444-450.
13. Yang X, Cullen SN, Li JH, et al. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004;40:375-379.
14. LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036-1042.
15. Palmer KR, Duerden BJ, Holdworth CD. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut 1980;21:851-854.
16. Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis or chronic ulcerative colitis. Hepatology 1981;1:632-640.
17. Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. In Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver, 10th edition. Philadelphia, USA: Lippincott-Raven Publishers, 2007, pp 665-677.
18. Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182-187.
19. Muratori P, Muratori L, Guidi M, Maccariello S, Pappas G, Ferrari R, at al. Anti-Saccharomyces cerevisiae antibodies and autoimmune liver diseases. Clin Exp Immunol 2003;132:473-476.
20. Erkelens GW, Vleggaar FP, Lesterhuis W, van Buuren HR, van der Werf SD. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet 1999;354:43-44.
21. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, Chari S, Lindor KD. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006;101:2070-2075.